Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenström macroglobulinemia in the United States.
Jorge J. Castillo(Dana-Farber Cancer Institute), Boxiong Tang, Keri Yang(Universidad San Carlos), Qian Zhao(Shanghai Open University), Rongzhe Liu(Pharmerit (United States)), Yu Wang(University of Florida Health), Xīn Gào(Qingdao University), Aileen Cohen(Düsseldorf University Hospital), Todd M. Zimmerman(Broad Institute), Gijs van de Wetering(Open University of the Netherlands)
Cited by 6
Related Papers
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
|Nature Genetics|2000|1.4k
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
|Cancer Cell|2014|1k
Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
|New England Journal of Medicine|2015|937
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
Essential requirement for two-pore channel 1 in NAADP-mediated calcium signaling
|The Journal of Cell Biology|2009|406